23rd Expert Committee on Selection and Use of Essential Medicines

The meeting of the 23rd WHO Expert Committee on the Selection and Use of Essential Medicines will be coordinated from WHO Headquarters, Geneva and held virtually on 21 June to 2 July 2021 to revise and update the WHO Model List of Essential Medicines (EML) and the WHO Model List of Essential Medicines for Children (EMLc).

The applications to be considered by the Expert Committee during the meeting are published below.

An Open Session of the meeting will be held virtually on Monday 21 June from 14:00 to 17:00 CEST. The Open Session provides an opportunity for individuals and partners external to the WHO to listen to an update on current and future activities of the EML Secretariat, and to provide comment on issues relating to the meeting agenda through short statements. The agenda for the Open Session is available here.

The presentations and public statements made during the Open Session will be published on this webpage. 

21 January 2021

Information for applicants - 23rd Expert Committee

The Secretary

Expert Committee on the Selection and Use of Essential Medicines

Medicines Selection, IP and Affordability (MIA)

Department of Health Products Policy and Standards (HPS)

20 Avenue Appia

CH-1211 Geneva 27

Email: emlsecretariat@who.int

Expert Committee Members and Temporary Advisors

Professor Zeba Aziz

Professor of Medical Oncology

Dr Rita Banzi

Head, Center for Health Regulatory Policies at the Mario Negri Institute

Professor Andrea Biondi

Paediatric oncologist

Professor Graham Cooke

Professor of Infectious Diseases

Professor Elisabeth de Vries

Medical Oncologist

Professor Antonio (Tito) Fojo

Professor of Medicine

Professor Myriam Khrouf

Professor Gilbert Kokwaro

Pharmacist

Dr Patrick Okwen

District medical officer

Assistant Professor Gabriela Prutsky Lopez

Assistant Professor of Pediatrics

Associate Professor Rachel Riera

Medical rheumatologist

Professor Andrew Roberts

Clinical haematologist

Prof Mike Sharland

Professor Shalini Sri Ranganathan

Professor in Pharmacology and Specialist in Pediatrics

Professor Fatima Suleman

Professor of Pharmaceutical Sciences

Ellen ‘t Hoen

Director, Medicines Law & Policy

Dr Verna Vanderpuye

Radiation and medical oncologist

Professor Indah S Widyahening

Professor in Community Medicine

Professor Mei Zeng

Paediatric infectious diseases specialist, Fudan University, China

Open session

Applications, reviews and comments

Applications for the 23rd Expert Committee

 

New Medicines

A.1  Anti-PD1 immune checkpoint inhibitors – non-small cell lung cancer – EML
A.2  Anakinra – juvenile idiopathic arthritis – EML and EMLc
A.3  Azacitidine – acute myeloid leukaemia – EML
A.4  BRAF/MEK inhibitors – metastatic melanoma – EML
A.5  Bupropion – smoking cessation – EML
A.6  Calcipotriol – psoriasis – EML and EMLc
A.7  Cefiderocol – infections due to multi-drug resistant organisms – EML
A.8  Cyclin-dependent kinase (CDK) 4/6 inhibitors – HR+/HER2- breast cancer – EML
A.9  Daratumumab – multiple myeloma – EML
A.10  Echinocandins – fungal infections – EML and EMLc
A.11  Enzalutamide – prostate cancer – EML
A.12  Equine rabies immunoglobulin – rabies post-exposure prophylaxis – EML and EMLc
A.13  Everolimus – subependymal giant cell astrocytoma – EMLc
A.14  Fluoride toothpaste – dental caries – EML and EMLc
A.15  Fulvestrant – metastatic breast cancer – EML
A.16  Glass ionomer cement – dental caries – EML and EMLc
A.17  Glecaprevir + pibrentasvir – hepatitis C virus infection – EMLc
A.18  Hypochlorous acid – disinfection, antisepsis, wound care – EML and EMLc
A.19  Ibrutinib – chronic lymphocytic leukaemia with 17p deletion – EML
A.20  Long-acting insulin analogues – diabetes mellitus – EML and EMLc
A.21  Methylphenidate – attention-deficit hyperactivity disorder – EML and EMLc
A.22  Multiple micronutrient supplement – antenatal supplement – EML
A.23  Osimertinib – EGFR+ non-small cell lung cancer – EML
A.24  Paliperidone and risperidone (long-acting) – schizophrenia – EML
A.25  Pertuzumab – metastatic breast cancer – EML
A.26  Rabies monoclonal antibodies (mAbs) – rabies post-exposure prophylaxis – EML and EMLc
A.27  Rasburicase – tumour lysis syndrome – EML and EMLc
A.28  Silver diamine fluoride – dental caries – EML and EMLc
A.29  Sodium-glucose cotransporter-2 (SGLT2) inhibitors – type 2 diabetes – EML
A.30  Sofosbuvir and daclatasvir – hepatitis C virus infection – EMLc
A.31  Sofosbuvir + velpatasvir – hepatitis C virus infection – EMLc
A.32  Sumatriptan – migraine – EML and EMLc
A.33  Tacrolimus – organ transplant rejection – EML and EMLc
A.34  Tislelizumab – Hodgkin lymphoma – EML
A.35  Tislelizumab – urothelial carcinoma – EML
A.36  Tocilizumab – juvenile idiopathic arthritis – EML and EMLc
A.37  Triamcinolone – juvenile idiopathic arthritis – EML and EMLc
A.38  Varenicline – smoking cessation – EML
A.39  Zanubrutinib – chronic lymphocytic leukaemia, small lymphocytic lymphoma – EML
A.40  Zanubrutinib – mantle cell lymphoma – EML 

Other changes to listing

Deletion

New Indications

I.1  Albendazole, mebendazole, praziquantel – taeniid cestode cysts – EML and EMLc
I.2  Antibiotics for bone and joint infections – EML and EMLc
I.3  Antibiotics for bronchitis and bronchiolitis – EML and EMLc
I.4  Antibiotics for ocular infections – EML and EMLc
I.5  Antibiotics for necrotizing fasciitis – EML and EMLc
I.6  Antibiotics for neonatal meningitis – EMLc
I.7  Antibiotics for intraabdominal infections in children – EMLc
I.8  Cancer medicines for children – various indications – EMLc
I.9  Cancer medicines for children – low grade glioma – EMLc
I.10  Cancer medicines for head and neck cancer – EML
I.11  Doxorubicin – rhabdomyosarcoma – EML and EMLc
I.12  Hydroxychloroquine – cutaneous lupus – EML
I.13  N-acetylcysteine – non-acetaminophen-induced acute liver failure – EML and EMLc
I.14  Simvastatin – polycystic ovary syndrome – EML
I.15  Tyrosine kinase inhibitors – Ph+ acute lymphoblastic leukaemia – EML
I.16  Vinorelbine – rhabdomyosarcoma – EMLc

New formulations/strengths

F.1  Abacavir 30 mg + lamivudine 15 mg + lopinavir/ritonavir 40mg/10mg fixed-dose combination – EML and EMLc
F.2  Amoxicillin + clavulanic acid 875 mg + 125 mg tablet – EML
F.3  Antibiotics – various new formulations/strengths – EML and EMLc
F.4  Bedaquiline 20 mg dispersible tablet – EML and EMLc
F.5  Delamanid 25 mg dispersible tablet – EML and EMLc
F.6  Dolutegravir 10 mg dispersible tablet – EMLc
F.7  Ethambutol IV infusion 1000 mg and 2000 mg – EML
F.8  Ethinylestradiol 0.12 mg + etonogestrel 0.015 mg vaginal ring – EML
F.9  Isoniazid IV injection 300 mg, 500 mg, 900 mg – EML
F.10  Pyrazinamide 500 mg tablet – EML
F.11  Rifampicin IV infusion 600 mg – EML
F.12  Rifapentine 300 mg tablet – EML and EMLc
F.13  Rifapentine 300 mg + isoniazid 300 mg fixed-dose combination – EML and EMLc

Reviews

Other matters